An additional inhibitory ligand frequently upregulated by tumor cells is the nonclassical HLA-G molecule, which is physiologically expressed at the fetal–maternal interface to maintain tolerance to the semi-allogeneic fetus but can be hijacked by tumor cells to inhibit effector cells as well as myeloid cells [84]. This evidence concerns the gene HLA-G and neoplasm.